Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 5/20 | 0.32 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656761 | 0.89 | PDK1 (0.32) | CXCR2CXCR1PPARGPPARAPDK1 | |
| SCHEMBL4664676 | 0.85 | CXCR2 (0.34) | CXCR2CXCR1PPARGPPARA | |
| SCHEMBL5138943 | 0.75 | CXCR2 (0.33) | CXCR2CXCR1PPARGPPARAGSK3B | |
| SCHEMBL4664643 | 0.75 | CXCR2 (0.33) | CXCR2CXCR1PPARGPPARAGSK3B | |
| SCHEMBL4662901 | 0.75 | CXCR2 (0.33) | CXCR2CXCR1PPARGPPARAGSK3B | |
| SCHEMBL4664608 | 0.74 | PDK1 (0.32) | CXCR2CXCR1PDK1GSK3B | |
| SCHEMBL4664660 | 0.72 | NPC1 (0.33) | CXCR2CXCR1 | |
| SCHEMBL4664836 | 0.72 | PARP1 (0.35) | CXCR2CXCR1 | |
| SCHEMBL14161718 | 0.69 | CNR1 (0.34) | PPARGPPARA | |
| SCHEMBL4664622 | 0.69 | TACR1 (0.32) | PPARGGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | CXCR2 4099/4885CXCR1 2925/4885PPARG 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.